dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Neeb, Antje |
dc.contributor.author | Herranz Martín, Nicolás |
dc.contributor.author | Arce Gallego, Sara |
dc.contributor.author | Buroni, Lorenzo |
dc.contributor.author | Yuan, Wei |
dc.contributor.author | Athie Cuervo, Alejandro |
dc.contributor.author | Casals, Teresa |
dc.contributor.author | Casanova Salas, Irene |
dc.contributor.author | Cordoba, Sarai |
dc.contributor.author | Castro, Natalia |
dc.contributor.author | González Rodríguez, Macarena |
dc.contributor.author | Morales Barrera, Rafael |
dc.contributor.author | Suárez Rodríguez, Cristina |
dc.contributor.author | Carles Galceran, Joan |
dc.contributor.author | Serra Elizalde, Violeta |
dc.contributor.author | Mateo Valderrama, Joaquim |
dc.contributor.author | Miranda, Susana |
dc.date.accessioned | 2021-06-30T12:35:05Z |
dc.date.available | 2021-06-30T12:35:05Z |
dc.date.issued | 2021-02 |
dc.identifier.citation | Neeb A, Herranz N, Arce-Gallego S, Miranda S, Buroni L, Yuan W, et al. Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. Eur Urol. 2021 Feb;79(2):200-211. |
dc.identifier.issn | 0302-2838 |
dc.identifier.uri | https://hdl.handle.net/11351/6112 |
dc.description | Inhibició de l’ATR; Resposta de danys a l’ADN; Càncer de pròstata |
dc.description.sponsorship | We gratefully acknowledge research funding for this work from Cancer Research UK, Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence ( CEO13_2-002 ), the Prostate Cancer Foundation (including Young Investigator Awards to Joaquin Mateo, Pasquale Rescigno, and Adam Sharp), Stand Up To Cancer, and the UK Department of Health through an Experimental Cancer Medicine Centre grant. Professor Johann de Bono is a National Institute for Health Research (NIHR) Senior Investigator; research at the Royal Marsden Hospital is supported by a Biomedical Research Centre grant. Part of this work was also funded by a Deparment of Defense CDMRP Impact Award (W81XWH-18-1-0756) to Joaquin Mateo and by Instituto de Salud Carlos III through Grant FI19/00280 to Sara Arce-Gallego, Grant CP19/00170 to Nicolás Herranz, and Grant PI18/01384 to Joaquin Mateo. The authors affiliated to VHIO acknowledge the “la Caixa” Foundation ( ID 100010434 ) for funding under agreement LCF/PR/PR17/51120011 and funding from Fundacion FERO and Moventia . This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 837900 . The funding organisations had no role in the design, conduction or data analysis of this project, neither in the manuscript preparation. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | European Urology;79(2) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Medicaments antineoplàstics - Ús terapèutic |
dc.subject | ADN - Reparació |
dc.subject | Pròstata - Càncer |
dc.subject.mesh | Prostatic Neoplasms |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | DNA Repair |
dc.title | Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.eururo.2020.10.029 |
dc.subject.decs | neoplasias de la próstata |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | reparación del ADN |
dc.relation.publishversion | https://www.sciencedirect.com/science/article/pii/S0302283820308368 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Neeb A, Miranda S, Buroni L, Yuan W] The Institute of Cancer Research, London, UK. [Herranz N, Arce-Gallego S, Serra V] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Athie A, Casals T, Casanova-Salas I, Cordoba S, Castro N] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Gonzalez M, Morales-Barrera R, Suarez C, Carles J, Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 33176972 |
dc.identifier.wos | 000609379800001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/FI19%2F00280 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/CP19%2F00170 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI18%2F01384 |
dc.relation.projectid | info:eu-repo/grantAgreement/EC/H2020/837900 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |